ANDA 209832, held by Amphastar Pharms Inc. Sodium Nitroprusside.
As of Nov 16, 2026, ANDA 209832 (Sodium Nitroprusside), held by Amphastar Pharms Inc, was first approved by FDA on Dec 18, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 18, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Nitroprusside25MG/ML ยท injectable;injection | Sodium Nitroprusside | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters